argenx

argenx builds therapies on the SIMPLE Antibody platform, which uses immunized llamas to produce unusually small, stable antibody fragments. These fragments can target epitopes that conventional antibodies cannot reach. The platform has yielded the FcRn blocker Vyvgart and a pipeline of candidates aimed at autoimmune neuromuscular and hematologic disorders.

Tim Van Hauwirmeiren has led argenx as CEO since co-founding the company in 2008. He oversees the executive team from the Amsterdam headquarters. Karl Gubitz joined as CFO in 2019 and manages financial strategy and treasury operations.

argenx is a fully integrated, publicly traded commercial-stage biopharmaceutical company. It conducts its own discovery, development, manufacturing and, in the United States, direct commercialization. This contrasts with venture-funded biotechs that typically rely on a large pharmaceutical partner for late-stage trials and sales.

argenx is not an investment firm or family office; it does not manage third-party capital or deploy a fund. It is a publicly traded biotech company that invests its own R&D and commercial budget—funded by product revenue and equity raises—into its internal drug pipeline.

The majority of argenx's $1.5 billion in 2024 revenue came from US sales of Vyvgart and its subcutaneous formulation Vyvgart Hytrulo. Additional revenue arrives through royalties and milestones from regional partners, including Zai Lab in Greater China (per argenx annual report, 2024).

argenx focuses on severe autoimmune diseases in neurology, hematology, and dermatology. Confirmed areas include generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, primary immune thrombocytopenia, and multifocal motor neuropathy. The firm has not pursued oncology or infectious disease.

No. argenx operates strictly as a drug development and commercialization company. It does not commit capital to external venture funds, make direct minority investments in other biotechs, or run a corporate venture arm.